CDRH Approves Variance for Visual Oasis LLC
Summary
FDA Center for Devices and Radiological Health (CDRH) approved a variance request from Visual Oasis LLC, allowing the firm to deviate from specific regulatory requirements applicable to its device operations. The variance approval letter, filed under docket FDA-2026-V-2432-0003, constitutes a binding regulatory decision from CDRH. The specific terms and conditions of the variance are documented in the attachment to this record.
Medical device firms facing challenges complying with specific CDRH regulatory requirements may request a variance — this approval demonstrates CDRH's willingness to grant such requests under appropriate circumstances. Firms considering a variance should document the regulatory constraint, propose specific alternative compliance measures, and demonstrate that equivalent public health protection is maintained.
About this source
Every FDA document on regulations.gov, the federal rulemaking portal. This is where the agency posts variances, advisory committee meeting notices, draft guidance for comment, citizen petition responses, and procedural rules that do not get a separate Federal Register slot. Around 240 a month. FDA's heavy regulations.gov use means tracking only the Federal Register misses a meaningful chunk of what the agency does day-to-day. Watch this if you manufacture devices, submit IND or NDA applications, run a lab, or advise sponsors on FDA process. GovPing publishes each posting with the docket, document type, division (CDER, CDRH, CFSAN), and comment window where one applies.
What changed
FDA CDRH approved a variance for Visual Oasis LLC, permitting the firm to operate outside standard regulatory requirements for its device-related activities. The variance represents a formal binding decision by the agency, authorized under FDA's device oversight framework.
Affected parties subject to similar FDA device requirements should review whether a variance request is appropriate if they face comparable regulatory constraints. Variance approvals are granted on a firm-specific and condition-specific basis, requiring direct engagement with CDRH.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Content
There are no documents available to view or download
Attachments 1
Variance Approval Letter from FDA CDRH to Visual Oasis LLC
More Information
- Author(s) CDRH
Download
Related changes
Get daily alerts for Regs.gov: Food and Drug Administration
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from FDA CDRH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when Regs.gov: Food and Drug Administration publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.